Caplight Directory>Companies>Averna Therapeutics-preview>Avernatx


Averna Therapeutics

Averna Therapeutics

Private
Watertown, MassachusettsHealthcare & Life Scienceshttps://avernatx.com/

Last Round

Series B

Mar 20, 2026

Total Funding Raised

$82M

Company Overview

Averna Therapeutics is a biotechnology company developing genomic medicines using RNA and lipid nanoparticle (LNP) technologies to durably and safely treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

gene insertion platformretrotransposon technologyall-RNA platformLNP deliverygene writinggenomic medicinesnon-viral gene therapyCRISPR alternativelarge gene insertionlipid nanoparticlesgenomic safe harborgene therapyRNA therapeuticsdrug discovery platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Averna Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Averna Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BMar 20, 2026
Series AJun 25, 2024
View all Funding Rounds

Key People

Founding team and executive leadership

Tal Zaks

Chairman And CEO

Executive Team

Averna Therapeutics Investors

Notable investors and investment history

InvestorRounds
Deep InsightSeries A
Innovation EndeavorsSeries A
OrbiMedSeries A, Seed
Novartis Venture FundSeries A
Arc VenturesSeries A
Delos Capital PartnersSeries A
InvusSeries A
View all Investors

Averna Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Averna Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Averna Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWatertown, Massachusetts
Employee Range54
Year Founded2022
Last FundingMar 20, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.